Spots Global Cancer Trial Database for RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor
Official Title: Raltitrexed Combined With Oxaplatin as Second Line Treatment for Advanced Malignant Biliary System Tumor
Study ID: NCT05148143
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor.
Detailed Description: The purpose of this study was to explore the safety and efficacy of raltitrexed combined with oxaplatin as second line treatment for advanced malignant biliary system tumor. Single arm，phase II study for patients with cholangiocarcinoma or gallbladder carcinoma after first line treatment failure to explore effection and safety of raltitrexed combined with oxaplatin as second line treatment；Sample size：50.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Name: Ying Yuan, Ph.D&MD
Affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
